Practitioner's Docket No. MPI00-185P1R2RCEM (FORMERLY MPI00-185P1R2M)

IN THE CLAIMS:

Please amend claims 83, 89, 93, 94, 100 and 104.

This listing of claims will replace all prior versions, and listings, of claims in the application:

STATUS OF THE CLAIMS:

1-82. (Canceled)

- 83. (Currently Amended): A method for identifying a candidate compound capable of interacting with a polypeptide selected from the group consisting of:
 - a) a polypeptide which is at least 95% identical to the amino acid sequence of SEQ ID NO:2; and
- b) a polypeptide encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:3;

wherein the polypeptide has protease activity; the method comprising:

- i) contacting a sample comprising the polypeptide with a test compound under conditions suitable for interaction; and
- ii) determining whether the polypeptide <u>interacts withbinds to</u> the test compound; thereby identifying a compound capable of interacting with the polypeptide.
- 84. (Previously Presented): The method of claim 83, wherein the sample is an isolated polypeptide, a membrane-bound form of an isolated polypeptide or a cell comprising the polypeptide.
- 85. (Previously Presented): The method of claim 84, wherein the cell is a mammalian cell.
- 86. (Previously Presented): The method of claim 83, wherein the interaction is in vitro.
- 87. (Previously Presented): The method of claim 83, wherein the candidate compound is selected from the group consisting of a peptoid, a peptidomimetic, a peptide, a phosphopeptide, an antibody, an organic molecule, and an inorganic molecule.
- 88. (Previously Presented): The method of claim 83, wherein the candidate compound is selected from the group consisting of: L-1-Chloro-3-tosylamido-4-phenyl-2-butanone, Soybean inhibitor, benzamidine,

Practitioner's Docket No. MPI00-185P1R2RCEM (FORMERLY MPI00-185P1R2M)

- p-Nitrophenyl-p-guanidino benzoate, Tosyl-L-lysine chloromethyl ketone, and Tosyl-L-arginine chloromethyl ketone.
- 89. (Currently Amended): The method of claim 83, wherein the candidate compound is a member of \underline{a} biological library.
- 90. (Previously Presented): The method of claim 83, wherein the candidate compound is detectably labeled.
- 91. (Previously Presented): The method of claim 90, wherein the label is selected from the group consisting of enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials and radioactive materials.
- 92. (Previously Presented): The method of claim 83, wherein the candidate compound is attached to a bead.
- 93. (Currently Amended): The method of claim 83, wherein the interaction of the candidate compound withto the polypeptide is detected by a method selected from the group consisting of:
 - a) direct detection of test compound/polypeptide binding;
 - b) a competition binding assay;
 - c) an immunoassay; and
 - d) a yeast two-hybrid assay.
- 94. (Currently Amended): A method for identifying a candidate compound capable of interacting with a polypeptide selected from the group consisting of:
 - a) a polypeptide comprising the amino acid sequence of SEQ ID NO:2; and
- b) a polypeptide encoded by a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:3;

the method comprising:

- i) contacting a sample comprising the polypeptide with a test compound under conditions suitable for interaction; and
- ii) determining whether the polypeptide <u>interacts with binds to</u> the test compound; thereby identifying a compound capable of interacting with the polypeptide.

Practitioner's Docket No. MPI00-185P1R2RCEM (FORMERLY MPI00-185P1R2M)

- 95. (Previously Presented): The method of claim 94, wherein the sample is an isolated polypeptide, a membrane-bound form of an isolated polypeptide or a cell comprising the polypeptide.
- 96. (Previously Presented): The method of claim 95, wherein the cell is a mammalian cell.
- 97. (Previously Presented): The method of claim 94, wherein the interaction is in vitro.
- 98. (Previously Presented): The method of claim 94, wherein the candidate compound is selected from the group consisting of a peptoid, a peptidomimetic, a peptide, a phosphopeptide, an antibody, an organic molecule, and an inorganic molecule.
- 99. (Previously Presented): The method of claim 94, wherein the candidate compound is selected from the group consisting of: L-1-Chloro-3-tosylamido-4-phenyl-2-butanone, Soybean inhibitor, benzamidine, p-Nitrophenyl-p-guanidino benzoate, Tosyl-L-lysine chloromethyl ketone, and Tosyl-L-arginine chloromethyl ketone.
- 100. (Currently Amended): The method of claim 94, wherein the candidate compound is a member of \underline{a} biological library.

1,

- 101. (Previously Presented): The method of claim 94, wherein the candidate compound is detectably labeled.
- 102. (Previously Presented): The method of claim 101, wherein the label is selected from the group consisting of enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials and radioactive materials.
- 103. (Previously Presented): The method of claim 94, wherein the candidate compound is attached to a bead.
- 104. (Currently Amended): The method of claim 94, wherein the interaction of the candidate compound withto the polypeptide is detected by a method selected from the group consisting of:
 - a) direct detection of test compound/polypeptide binding;
 - b) a competition binding assay;
 - c) an immunoassay; and
 - d) a yeast two-hybrid assay.